Bristol-Myers Squibb Company ((BMY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Bristol-Myers Squibb is initiating a Phase 3 clinical study titled A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Adolescent Participants (12 Years to Less Than 18 Years) With Moderate to Severe Plaque Psoriasis. The study aims to assess the effectiveness, safety, and drug levels of Deucravacitinib, a promising treatment for adolescents suffering from moderate to severe plaque psoriasis.
Intervention/Treatment: The study will test Deucravacitinib, an active drug, against a placebo. Deucravacitinib is designed to treat plaque psoriasis by targeting specific pathways involved in the disease process.
Study Design: This interventional study is randomized with a parallel assignment. It uses a double-blind approach, meaning neither the participants nor the investigators know who receives the drug or placebo. The primary goal is treatment evaluation.
Study Timeline: The study is not yet recruiting, with an estimated start date of August 26, 2025. The study was first submitted on May 13, 2025, and last updated on July 29, 2025. These dates are crucial for tracking the study’s progress and potential impacts on the market.
Market Implications: The initiation of this study could positively influence Bristol-Myers Squibb’s stock performance and investor sentiment, given the potential of Deucravacitinib to address unmet needs in adolescent psoriasis treatment. Competitors in the dermatological treatment space may also feel the pressure to advance their own research and development efforts.
Closing Sentence: The study is ongoing, with further details available on the ClinicalTrials portal.